It is a major risk factor for cirrhosis and liver cancer. And because treatment options are limited, MASH is the most common liver disease in the United States and the second leading cause for liver transplants in the United States after cirrhosis caused by chronic hepatitis C infection.
A better understanding of the pathological processes that drive MASH is critical to creating effective treatments. In a new paper published August 19, 2024 in PNAS, a team of scientists from Sanford Burnham Prebys, the University of California San Diego School of Medicine and elsewhere, describe the complex interplay between diseased liver cells and macrophages — a type of white blood cell whose jobs include killing and removing harmful cells and pathogens and helping to spur normal healing.
Read more >>
|